A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

NCT03395080 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer
Uterine Cancer
Ovarian Cancer
Carcinosarcoma

Interventions

DRUG: Paclitaxel
DRUG: 300mg DKN-01
DRUG: 600mg DKN-01

Sponsor

Leap Therapeutics, Inc.